The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely through paracrine signaling rather than engraftment and differentiation, a reframing captured in Arnold Caplan’s proposal to rename them “medicinal signaling cells.” What hasn’t matured is the public’s understanding of any of it. [Read more…]
China’s First Approved MSC Therapy, Ruibosheng, Hits the Market at a Fraction of Global Pricing
For years, the promise of mesenchymal stem cell (MSC) therapy has faced a stubborn barrier: cost. Even as regulators in South Korea, Japan, and other countries have cleared MSC-based products for commercial use, pricing for advanced cell therapies has often reached six figures, limiting access to a relatively small segment of patients and healthcare systems.
China’s first approved MSC therapy is challenging that assumption. Ruibosheng (amimestrocel injection), developed by Platinum Life Excellence Biotech, has entered the Chinese market at a price point that is a fraction of comparable cell therapies globally, highlighting how manufacturing innovation and scale may reshape the economics of regenerative medicine.
The National Medical Products Administration (NMPA) granted conditional approval to Ruibosheng on January 2, 2025, making it the first MSC-based cell therapy approved for market in China. The therapy was cleared for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) with predominant gastrointestinal involvement in patients aged 14 and older. Since receiving regulatory approval, Ruibosheng has progressed into commercial distribution and clinical adoption across Chinese hospitals. [Read more…]
Longevity Medical Institute® Launches Advanced Intranasal Regenerative Neurological Therapy Platform
Non-invasive nose-to-brain delivery system expands treatment options for patients with neurological disorders as an alternative to intrathecal administration.
SAN JOSé DEL CABO, BAJA CALIFORNIA SUR, MEXICO, July 23, 2026 — Longevity Medical Institute® today announced the launch of its Regenerative Neurological Therapy Program, featuring an advanced intranasal delivery platform designed to transport regenerative therapies toward the brain through the nasal cavity. The technology expands the institute’s comprehensive neurological program by offering patients a non-invasive alternative to intrathecal administration for selected neurological conditions.
[Read more…]
RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers
Distribution agreement gives U.S. customers a single-vendor source for high-quality cells, bioprocess media, and recombinant growth factors—giving cell and exosome therapy developers a single, translation-friendly source for critical raw materials
FREDERICK, MD., July 7, 2026 — RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins. Under the agreement, customers in the United States can now order Qkine’s full range of translation-friendly research use only (RUO) growth factors and cytokines directly from RoosterBio. [Read more…]
Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 11, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the therapeutic potential of allogeneic mesenchymal stem cell therapies for diabetic foot ulcers, one of the most serious and difficult-to-treat complications of diabetes. The publication adds to the growing body of evidence supporting stem cell-based approaches in chronic wound care and reflects Longevity Medical Institute’s broader investment in clinical research, diagnostics, and regenerative medicine infrastructure. [Read more…]
- 1
- 2
- 3
- …
- 8
- Next Page »